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Abstract
Germline/somatic BRCA-mutated ovarian carcinomas (OC) are associated to have better response with platinum-based
chemotherapy and long-term prognosis than non-BRCA-associated OCs. In addition, these mutations are predictive
factors to response to Poly(ADP-ribose) polymerase (PARP) inhibitors. Different positioning papers have addressed
the clinical recommendations for BRCA testing in OC. This consensus guide represents a collection of technical recom-
mendations to address the detection of BRCA1/2 mutations in the molecular diagnostic testing strategy for OC. Under
the coordination of Spanish Society of Pathology (SEAP-IAP) and the Spanish Society of Human Genetics (AEGH),
these recommendations have been developed by pathologists and geneticists taking into account previously published
recommendations and their experience in the molecular characterization of these genes. Since the implementation of
BRCA testing as a predictive factor can initiate the workflow by testing germline mutations in the blood or by testing
both germline and somatic mutations in tumor tissue, distinctive features of both strategies are discussed. Additionally,
the recommendations included in this paper provide some references, quality parameters, and genomic tools aimed to
standardize and facilitate the clinical genomic diagnosis of OC.
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Ovarian cancer (OC), the most aggressive gynecologic
malignancy, produced 42,704 deaths in Europe in 2012
(1). This high lethality can be attributed, among other
factors, to its frequent late stage at presentation and lim-
ited treatment options. OC is a heterogeneous disease that
includes five main histological types [53]: high-grade se-
rous carcinoma (HGSC), low-grade serous carcinoma
(LGSC), endometrioid carcinoma (EOC), clear cell carci-
noma (CCC), and mucinous carcinoma (MC). These his-
tological subtypes have different epidemiological and ge-
netic risk factors, and they differ also with respect to
precursor lesions, pattern of tumor spread, prognosis,
and response to common therapy approaches, such as che-
motherapy, hormone therapy or poly(ADP-ribose) poly-
merase (PARP) inhibitors (PARPi) [44]. For example,
HGSC, representing 70% of late-stage tumors, is associ-
ated in some cases with a specific precursor lesion (serous
intraepithelial carcinoma of the fallopian tube), and has a
poor prognosis, even though approximately 50% of the
patients show an initial good response to platinum thera-
py. From a molecular point of view, approximately 95%
of HGSC carry TP53 mutations and about 50% have ho-
mologous recombination deficiency (HRD) due to alter-
ations in genes involved in the homologous recombina-
tion DNA repair pathway [63].
In the TCGA cohort, 20% of HGSC carried mutations in
BRCA genes: 9% germline mutations in BRCA1, 8% germline
mutations in BRCA2, and 3% somatic mutations affecting one
of the two genes [63]. In addition, BRCA1/2 mutations (both
somatic and germline) have been reported in 15% and 10% of
EOC and CCC, respectively [51].
Identification of BRCA-mutated OC patients is important
for the following reasons:
& To identify BRCA germline mutation carriers (40% of pa-
tients with OC and pathogenic germlineBRCA1/2 variants
have no family history of breast or ovarian cancer).
& Germline/somaticBRCA-mutated OCs are associated with
better response to platinum-based chemotherapy (the stan-
dard of care in patients with late-stage OC) and long-term
prognosis than non-BRCA-associated OCs.
& Germline/somatic BRCAmutation is a predictive factor to
response to PARPi.
Current recommendations for BRCA testing vary among
European countries. Thus, Vergote et al. [66] observed differ-
ences regarding testing criteria based on the histology of the
tumors. Testing was offered for all ovarian cancers in the
Netherlands, Italy, Scotland, and the Czech Republic, for all
non-mucinous high-grade carcinomas in France and for all
high-grade serous carcinomas in Germany, Belgium, and
Portugal. Recently the ESMO-ESGO consensus conference
recommended testing for BRCA1/2 mutations for all patients
with non-mucinous ovarian cancer [15].
In Spain, a national consensus issued by the Spanish
Society of Pathology (SEAP-IAP) and the Spanish Society
of Medical Oncology (SEOM) recommended that germline
BRCA1/2 mutation testing should be offered to all patients
with high-grade non-mucinous ovarian carcinomas. In addi-
tion, somatic testing should be considered in cases negative
for germline mutations. At present, although the consensus
recognizes the potential role of testing other HRD genes, its
clinical implementation is still low [49].
Provided that the clinical recommendations have been ad-
dressed by different positioning papers [31, 49, 66], our consen-
sus guide represents a collection of technical recommendations to
address the detection of BRCA1/2 mutations in the molecular
diagnostic testing strategy for OC. Under the coordination of
Spanish Society of Pathology (SEAP-IAP) and the Spanish
Society of Human Genetics (AEGH), these recommendations
have been developed by pathologists and geneticists taking into
account previously published recommendations [19] and their
experience in the molecular characterization of these genes.
An important question regarding the implementation of
BRCA testing as a predictive factor is whether to initiate the
workflow by testing germline mutations in the blood or by
testing both germline and somatic mutations in tumor tissue.
Distinctive features of both strategies are summarized in
Table 1. Additionally, the recommendations included in this
paper provide some references, quality parameters, and geno-
mic tools aimed to standardize and facilitate the clinical geno-
mic diagnosis of OC.
Pre-analytical Considerations
Any pre-analytical factor that modifies the quality of the sam-
ple could potentially impact in the results [29, 33]. A recent
publication has reviewed pathology practices to ensure molec-
ular integrity biospecimens for precision medicine [17]. The
labeling, preparation, and formaldehyde fixation (if necessary)
and the delivery to the laboratory in which the study is per-
formed are the responsibilities of the professional in charge of
obtaining the sample. The laboratory performing the molecu-
lar study must be able to handle different types of samples.
The key recommendation in pre-analytical process in both
tissue and blood samples are summarized in Table 2.
Briefly, in tissue samples, the cold ischemia time (Cit), the
period of time since tissue is obtained and its fixation, impacts on
DNA, RNA, and proteins in large surgery specimens, like ovary
tumors [6]. To limit this effect, standard procedures in tissue
preservation in fixative process or freezing in optimum cutting
temperature (OCT) compound are recommended for optimum
DNA recovery. However, DNA is more frequently isolated from
formalin-fixed paraffin-embedded (FFPE) samples and is highly
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recommended that the tissue fixation procedure be controlled by
the pathology laboratory [18, 59, 68] [57, 61] [22]. Finally, mor-
phological diagnosis should always include the type and grade of
the tumors in order to gain insight into genotypic/phenotypic
correlations. Representative tumor area selection and percentage
of malignant cells must be performed by a well-trained patholo-
gist on an H&E section. Aminimum of 30% of tumor cellularity
is recommended to guarantee the detection of a variant through
molecular techniques [21].
Blood samples should be collected in tubes with either
EDTA or nucleic acids preserving agents, and processed im-
mediately after its extraction, ideally in less than 30 min when
tubes contain no preservatives [36] and following standard
procedures. The leucocyte fraction is an excellent source for
the study of germline DNA, being the standard nowadays.
The serum contains DNA from leucocytes, in worse preserva-
tion conditions, and the plasma contains circulating free DNA.
However, the study of germline mutations can be performed
using also whole blood without fraction separation.
DNA extraction based on precipitation, magnetic beads, or
silica-based membrane columns shows similar efficiency up-
on quality and concentration of the DNA obtained [42].
However, it is highly recommended that DNA extraction is
standardized and performed using CE-IVD marking tech-
niques in both manual and automatized processes. These pro-
cesses must be performed strictly following the manufac-
turer’s guidelines and standardized procedures after a priva-
tive validation process prior to the clinical use [10].
Measures for assuring full traceability of the sample and its
derived products to avoid cross-contamination are critical. For
tissue samples, precautions such as the preparation of free nucleic
acid plastic containers, the use of PCR quality water for floating
baths, and the systematic cleaning of devices with DNA and
RNA removers [20] should be taken.
The use of spectrophotometry (Nanodrop), fluorometry
(Qubit), and/or PCR fragment (Agilent Bioanalyzer) systems is
recommended for the quantification and qualification of the
DNA obtained, especially in tissue sample where formaldehyde
and paraffin treatments produce the fragmentation of the DNA
[42]. Isolated DNAmust be kept at –20 °C, while PCR products
and library prepared should be kept in a different freezer at –20 or
–80 °C to avoid cross-contamination. There is not a large amount
of information about the impact of the storage time on the quality
of the DNA or amplification products, but, in general, their sta-
bility is assumed for several years [43].
Analytical Phase: Next-Generation Sequencing (NGS)
Library preparation adapts the nucleic acids to be sequenced,
including the fragmentation of the DNA by either physical
(sonication) or enzymatic (endonuclease cocktail or
transposase-mediated fragmentation) methods, adapter linkage,
and the enrichment of the regions of interest (ROI). There are
several strategies for ROI enrichment, and differences should be
taken into account prior to the sequencing process. Amplicon-
based methods are characterized by shortened and simplified
Table 1 Characteristics to take into account of the BRCA testing on blood and tumor samples
Blood BRCA testing Tumor BRCA testing
Pre-analytical considerations Pre-analytical conditions less critical Risk of delayed fixation and overfixation
Analytical phase NGS Detection of germline mutations Detection of germline and somatic mutations
Methods must detect at least ≥50%
variant allele frequency
Methods must detect at least ≥5–10%
variant allele frequency
Recommended average sequencing
coverage between 50 × –250× reads
Recommended average sequencing coverage between
500 × –2000× reads
Possible to detect large deletions/rearrangements Difficult to detect large deletions/rearrangements
Unlikely to generate false-positive SNVs Fixation artifacts/generation of false-positive SNVs
Well-established validated NGS methods Not fully available validated NGS methods
Post-analytical phase NGS (I) Straightforward analysis Complex analysis
Simple and validated filter pipelines More complex. Sensitive to filtering methods
Heterozygous pathogenic
variants (VAF = 50%)
Heterozygous pathogenic variants (VAF < 50%)
False-negative results (VAF < 5–10%)
Post-analytical phase NGS (II) Possibility to miss a group of patients
(<10%) that could benefit for PARPi therapy
Identification all possible patients that can benefit
for PARPi therapy based on BRCA testing
Low percentage of VUS expected
(<10% in a well characterized population)
Possibility of finding novel variants for which there is
no information in databases and increase the % of VUS
More information needs to be included in the report
which makes it more laborious
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preparation protocols also requiring smaller DNA inputs and no
fragmentation step. This is especially relevant when working
with small FFPE clinical specimens. This technology provides
higher on-target values, while hybridization capture-based
methods demonstrated higher uniformity rate. However both ap-
proaches have demonstrated technical and clinical utility in diag-
nostic procedures [56].
Molecular barcodes are introduced to allow sample identifi-
cation and combination in a unique sequencing reaction [32].
After library preparation, appropriated quality control steps
should be performed to determine the feasibility of the sample
to continue the procedures. These quality control steps include
quantification of the library, size analysis of the fragments, and
quantitative PCR using adapter to check the real amplifiability of
the library fragments.
The combination of sequencing platforms and commercially
available sequencing kits offers a variety of options for next-
generation sequencing (NGS) studies [9, 30, 37]. However, it is
important to acknowledge that cost efficiency and acceptable
turnaround times will only be achieved by fully exploiting the
capacity of the sequencing runs, so sequencing strategy should
be chosen based on the laboratory NGS testing demand [58]. In
this regard, the use of commercially available panels (see
Table 3) for BRCA1/2 testing is the most common praxis in
clinical routine. Since they have been validated by the manufac-
turers, their implementation has turned out to be easier.BRCA1/2
genes are included in several NGS panels, such as BRCA panels
in which only these genes are tested, hereditary cancer panels
including other cancer-predisposing genes, and somatic cancer
panels designed to detect oncogenic mechanisms in FFPE
samples.
In conclusion, the choice of the NGS panel for library prepa-
ration will depend on the type of study (somatic, germinal, or
both) and the sequencing strategy available in the institution [56].
A goodNGS testing strategy ofBRCA1/2 genes should allow the
identification of single nucleotide variants (SNVs) and small
insertions-deletions (indels) in all coding exons and exon-intron
boundaries, as well as CNVs, although the latest can be deter-





Sample type Key recommendations
Tissue sample Follow College of American Pathologists guidelines for
fixation of tissue samples (Hammond 2010), 8–48 hr,
depending on size of specimen
Vacuum and controlled temperature
Controlled parafinization protocols
Large samples must be properly handle by a pathologist or
well-trained personnel in order to assure formaldehyde
penetration and adequate fixation
Cytological samples also useful because alcoholic fixatives
excellently preserve DNA
Sample must contain a percentage of tumor cells that is at
least 30%. Avoid inflammation, immune infiltrates, and necrosis
Morphological diagnosis should always include the type and
grade of the tumors in order to gain insight into
genotypic/phenotypic correlations
Decalcification reduces DNAyield and quality. If needed,
avoid acid decalcification
Blood sample EDTA or nucleic acids preserving agent tubes
Sample processed immediately after its extraction (ideally in less
than 30 min when tubes contain no preservatives)
Tubes treated with heparin must be avoided, since it can inhibit PCR reaction
Centrifugation of the blood sample must be performed at 4 °C
using low speed (1000–2000 g for 10 min), to split the hematic
pellet from the fractions corresponding to the buffy coat and the plasma
Higher centrifugation speed and time should be avoided to
prevent platelet and leucocyte lysis
Fractions obtained after blood centrifugation can be stored at –20 °C
during short periods of time and at –80 °C for long terms
Leucocyte fraction, serum, plasma, and whole blood are acceptable
for germline DNA (leucocytes preferred)
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Post-analytical Phase I: Analysis and Filtering
of Variants
Data analysis is performed after the sequencing process and can
be divided into three stages: primary, secondary, and tertiary
analysis. The primary analysis consists of base calling and
demultiplexing processes and is performed automatically by spe-
cific software on the sequencer. Base calling is the conversion of
raw data to nucleotide reads, and the demultiplexing process
separates data from each sample according to specific barcodes.
A quality control of the run is also performed at this stage by the
technical staff to verify the amount of the library pool loaded as
well as the general sequencing process. Although there are dif-
ferent file formats to store primary analysis results, FASTQ and
BAM are the most commonly used.
The secondary analysis can be done on the same sequencer or
employing external pipelines or workflows [26]. Quality control
of each sample reads; elimination of low-quality reads, adapters,
primers, and duplicated reads; and alignment are the basic pro-
cesses along this step. During the alignment step, each read is
compared against the reference sequence of the human genome
to locate its original position, which can be improved using the
distance and orientation of paired-end reads [50]. Themostwide-
ly used mapping file format is the Sequence Alignment Map
(SAM) and its compressed version Binary Alignment Map
(BAM) [55]. Depending on the enrichment technique used for
library preparation, after the initial mapping, duplicate reads
might be removed to avoid false-positive variant calls due to
unwanted clonal amplification of reads with sequence artifacts.
Duplicate reads can be eliminated based on the genomic position
or because they share a UMI (unique molecular identifiers). The
addition of UMIs before PCR amplification discriminates be-
tween alleles arising from the same genomic locus and sequenc-
ing reads produced by PCR amplification [13]. After alignment,
genome browsers, like the Integrative Genomics Viewer (IGV),
propose the majority or highest-quality base for each position
[41]. Finally, reads can be recalibrated, and the indels realigned,
by consensus, to the left [55].Variant calling is the stepwhere the
variants (bases that differ from the reference genome) are identi-
fied for each sample. Variant calling format (VCF) is the standard
file to store the information of variants (one line per variant). The
variant information from different individuals can be stored in a
single VCF file. Variant filtering criteria vary depending on the
NGS platform and the enrichment system used, like the mini-
mum number of reads covering the base, as well as theminimum
average coverage and depth accepted for a variant. In the case of
tumor samples, the variant allele frequency (VAF) varies in func-
tion of the tumoral cellularity present in the sample and the tumor
proportion with the alteration [50] (the minimum average read
depth to detect variants with a VAF of 5% should be 500X). An
accurate filtering increases the quality of the results, e.g., filtering
out reads with a quality value <Q30 can greatly improve the
dataset, as quality score of 30 represents an error rate of 1 in
1000X [55] with a corresponding call accuracy of 99.9%. In
BRCA1/2 the most frequent variants observed are single nucleo-
tide polymorphisms (SNPs), indels, single nucleotide variants
(SNVs), and copy number variations (CNVs) [50]. One limita-
tion of current NGS approaches is the ability to reliably detect
CNVs, since NGS mainly depends on the panel employed and
the quality of the DNA samples. In somatic test, the high hetero-
geneity increases the background noise in the CNV copy plot,
leading to frequent false results. Several bioinformatics tools for
CNVassessment have been developed [38].
The tertiary analysis consists of the functional annotation
of the variants identified in the individuals and the selection of
pathogenic variants (see post-analytical phase II section). In
this stage, the technical and biological information is integrat-
ed to interpret the variants detected through the sequencing
process [50, 55].
Data analysis is the most complex and time-consuming stage
of the entire NGS process; therefore, qualified personnel are
required, either a geneticist or a molecular biologist appropriately
trained to handle the complex classification of genetic variants
across BRCA genes. In case of somatic mutation analysis, the
importance of the pathologist expertise is stressed, since the im-
pact of pre-analytical conditions, selection of the appropriate tis-
sue fragment, and interpretation of the results in the light of
microscopical appearance are crucial, providing an integrated
molecular pathology report. BRCA1/2 genes have a large size,
and many clinically relevant variants have been located through-
out the whole coding region of the genes that have to be entirely
analyzed. The quality of the DNA from FFPE samples is typi-
cally low, and the tumor percentage is variable; thus the variants
can be identified at allelic frequencies less than 50%, leading to a
complex identification of the variants, compared to peripheral
blood samples. For all these reasons, the accurate pipeline vali-
dation and the staff experience play an important role in the
BRCA1/2 genes analysis, which is evenmore crucial when tumor
samples are studied.
Post-analytical Phase II: Variant Interpretation
Clinical classification should be done following the guidelines
developed by the American College of Medical Genetics and
Genomics /Associa t ion for Molecular Pathology
(ACMG/AMP) [5, 27, 54] and the (evidence-based network
for the interpretation of germline mutant alleles) ENIGMA
consortium [25] (an adaption of the ACMG/AMP rules to
the specific case of BRCA1/2). The ACMG/AMP guidelines
propose 28 classification criteria (frequency in control popu-
lations, co-segregation, functional data, and in silico predic-
tions, among others), categorize them according to their
strength for a benign or pathogenic assertion, and propose
rules to combine different criteria into a final five-tier classi-
fication of variants that reflects their probabilities of being
clinically relevant (see Table 4).
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Most genetic variants will be readily classified as benign
based on allele frequency in control population. Indeed, an
allele frequency ≥0.01 in any general continental population
dataset of at least 2000-observed alleles is considered a benign
stand-alone criterion for a BRCA1/2 variant [5, 25]. There are
many databases reporting frequencies [11, 23, 24, 47, 48] .
One of the most widely used database to identify non-
pathogenic variants is the Genome Aggregation Database
(gnomAD) [11], which contains information about 125,748
exomes and 15,708 genomes from unrelated individuals.
Other variants will be readily classified as likely pathogenic,
based on its location in a canonical splice site, or pathogenic,
based on the generation of a premature termination codon not
located in the last exon of the gene (PTC-NMD).
We will focus here on the variants of unknown significance
(VUS), which are typically missense or intronic variants. A
high proportion of the former VUS in BRCA1/2 has been
classified, thanks to international efforts that have allowed
compilation of evidences and standardization of classification
rules [5, 25, 27, 28, 52, 54]. There are three reputable data-
bases [1, 39, 46] that compile accurate information on
BRCA1/2 variants classification based on multiple evidences
from different sources combined into a Bayesian model to
generate a posterior probability and validated by an expert
panel [28]: ClinVar, BRCA Exchange, and BRCA Share. In
ClinVar, the classification is reliable only if the “review status”
contains three stars, meaning that it has been validated by the
ENIGMA [25] expert panel, while BRCA Exchange [1] pro-
vides the same classification as ClinVar in a more user-
friendly environment and more detailed information [14], in-
cluding a mobile app that provides reclassification updates on
variants of interest. On the other hand, BRCA Share™ [7]
compiles data from 16 academic laboratories performing
BRCA1/2 testing in France. It is important to highlight that
other databases or levels of curation (e.g., <3 stars in
ClinVar) might not be reliable. For that reason, variant inter-
pretation requires expertise and should be performed by a
specialist, avoiding automatic interpretations.
Most variants remaining of uncertain significance after fil-
tering are rare missense, synonymous, or intronic variants
(MAF < 0.01). If pathogenic, missense variants are often as-
sumed to impact the protein structure/function, but the possi-
bility of the underlying nucleotide change leading to aberrant
splicing should not be disregarded [65]. Over 400 in silico
tools have been developed to predict the functional impact
of missense changes [2], including Align GVGD, PolyPhen,
SIFT, andMutationTaster. None of these tools is gene specific,
but due to the clinical relevance of BRCA1/2 testing, Align
GVGD has been calibrated to predict the probability for any
missense change in these two genes to be pathogenic [54].
In silico tools predicting splicing alterations are far
more accurate. MaxEntScan has been calibrated to predict
the prior probability of any possible substitution in
BRCA1/2 to be pathogenic due to an impact on splicing
[64]. Due to its accuracy, the ENIGMA expert panel has
included a specific role for well-calibrated splicing tools
in its classification process. More specifically, rare synon-
ymous or intronic variants (IVS + 20_IVS–40 range) not
predicted to affect or create splice sites are considered
likely benign. By contrast, variants predicted alter splicing
cannot be considered automat ical ly pathogenic,
distinguishing between spliceogenicity (the variant is al-
tering splicing) and pathogenicity (the splicing alteration
is pathogenic). For that reason, in the absence of RNA
analysis, variants located in the acceptor site of BRCA1
exons 8, 9, 10, 13, and 14 and BRCA2 exon 12 and var-
iants located in the donor site of BRCA1 exons 9 and 10
and BRCA2 exon 12 should be considered VUS. Align
GVGD- and MaxEntScan-calibrated predictions are up-
dated periodically [35] and have been incorporated as
well into the BRCA Exchange detail view.
Splicing Studies
The most likely mechanism underlying the pathogenic nature
(if any) of synonymous and intronic variants is aberrant splic-
ing. A recent report by the ENIGMA consortium describes
some aspects relevant to design, perform, and interpret ade-
quately studies performed by RT-PCR in blood derived RNA
from carriers. [67]. If the study demonstrates that the variant
Table 4 IARC five-tier classification, adapted from [49]. *Based on the recommendations from the EMQN (European Molecular Genetics Quality
Network)
Class Probability (quantitative) Description (qualitative) Report? Predictive testing? Management of carriers Research testing
5 >0.99 Definitely pathogenic Yes Yes Full high-risk guidelines No
4 0.95–0.99 Likely pathogenic Yes Yes Full high-risk guidelines May be helpful
3 0.05–0.949 Uncertain Yes* No Variant irrelevant to risk assesment
(Manage risk based on family history)
May be helpful
2 0.001–0.049 Likely not pathogenic No* No Variant irrelevant to risk assesment
(Manage risk based on family history)
May be helpful
1 <0.001 not Pathogenic No* No Variant irrelevant to risk assesment
(Manage risk based on family history)
No
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allele produces only PTC-NMD transcripts and/or transcripts
lacking the coding sequence of critical functional domain, it
can be classified as pathogenic. If RNA from carriers is not
available, or if the splicing outcome observed does not permit
a definitive classification, complementary studies performed
by validated reporter minigenes might be useful.
Reporting Germline and Somatic BRCA1/2 Results
The laboratory must determine which variants, according to
its clinical significance, are informed and how the results will
be communicated. For BRCA1/2 genes, there is a broad inter-
national consensus to use the five-classes classification [56].
All pathogenic and likely pathogenic variants (classes 5 and 4,
respectively) must be informed; reporting of VUS (class 3) is
recommended, with the statement that it should not be used in
a clinical decision-making context.
The report should contain the identification data of the
patient and his/her diagnosis, the name of the physician
requesting the test , and the reason for referral .
Methodology of the diagnostic test performed and its
scope should be accurately described (see Table 5).
Reports should contain a summary of the results clearly
framed and a discussion of the clinical relevance and the
limitations of the test. Reports must be signed by at least
two qualified faculties who have reviewed, approved and
interpreted the results and should clearly identify the lab-
oratory and its contact information, as well as its
accreditations-certifications and participation in quality
assessments. The report must be clear and concise; one
page is the preference for the European Molecular
Quality Network (EMQN) [3] and the Genomics Quality
Assessment (GenQA) [4]; and two are accepted when
reporting NGS results to provide the information specified
here (important content information is described in
Table 5) [12, 45, 60] and other information that the labo-
ratory wish to report should be provided as supplementary
and clearly separated from the main report. The laboratory
must agree with the clinical team and the delivery time of
the results; although considering its relevance for certain
therapeutic decisions, the laboratory should ensure a fast
delivery time in cases that need it.
Table 5 Recommended content information for a proper report of BRCA1/2 mutational test
Sample • Description of the sample analyzed Peripheral blood DNA, DNA from FFPE tissue
• In the case of studies carried out on tumor
samples, indicate the suitability of the sample
Neoplastic content estimation and cellularity,
limit of detection of the test performed
(the percentage of mutated allele that is




• Description of the analytical determination Horizontal extent of the region analyzed, sequencing
platform and chemistry used, methodology of enrichment
of the genes, steps of bioinformatics pipeline
• Description of the NGS relevant quality parameters Global depth of coverage, minimum coverage of all
analyzed bases, percentage of bases with a coverage
>30X (500X in somatic and must be accompanied by the
limit of detection of allelic frequency)
• Has the analysis of the number of copies
of the genes been performed?
YES (by MLPA, NGS, others) or NO
• Limitations of the test Analytical sensitivity, detection of deep intronic variants or
large indels, existence of areas of low coverage, the
accurate sequencing of homopolymer regions (>8 nt)
• Genes reference sequence number/version Database version for annotation and HGVS (Human
Genome Variation Society) nomenclature for cDNA
and amino acid changes
Variants
• Definition of the criteria used to filter out variants Information from databases supporting pathogenicity or
the potential therapeutic implications
Recommendations
• Negative germline reports should advise a tumor study for the determination of somatic BRCA1/2 mutations
• Positive BRCA1/2 somatic reports should recommend a germline study to determine the nature of the
mutation identified and its correct interpretation in the personal and family context of cancer
• Reports with positive BRCA1/2 mutation should recommend the referral of the patient to a genetic counseling
unit for the purpose of an adequate interpretation of the results and their personal and family implications
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Recommendations and Quality Programs
In order to ensure a correct clinical practice, it is recommended
that laboratories have certification and accreditation to perform
molecular genetic studies. Certification is defined by ISO as the
“Procedure by which a third party gives written assurance that a
product, process or service conforms to specific requirements.”
Certification is performed typically according to the ISO9001-
2015 standard, and, although provides a quality measure, it does
not ensure that the laboratory has demonstrate technical compe-
tence to produce valid data and results. The requirements of
certification address the quality management system (QMS)
and include procedures and a quality manual, document control,
define non-conformities (NCs) and corrective and preventive
actions (CAPA), perform internal audits, and enhance customer
satisfaction, but it does not necessarily include requirements of
technical or analytical competence.
Accreditation is defined by ISO as the “Procedure by which
an authoritative body gives formal recognition that a body or
person is competent to carry out specific tasks.” The standard
developed by ISOmost frequently used inmedical laboratories is
the ISO15189 and ensures technical competence of a laboratory
to perform specific types of testing by complying with specific
management and technical requirements. The accreditation pro-
cess also considers the QMS, like certification, but it has addi-
tional formal requirements of technical competence, including
initial and continuous training of personnel, validation of
methods and instruments, as well as internal and external quality
control [8]. As a result, certification (typically according to the
ISO9001 standard) should not be interpreted to mean that a lab-
oratory has demonstrated the technical competence to produce
valid data and results.
There is also a difference in the body that carries out the
assessment and delivers the certification or accreditation certifi-
cate. Laboratories applying for ISO 9001 certification will be
audited by a certification body, a third party that is accredited
by an accreditation body. Each country has multiple certification
bodies, but there is only one recognized national accreditation
body (NAB) in each country that assesses laboratories against
internationally agreed standards (Regulation (EC) No 765/2008).
In Spain this is Entidad Nacional de Acreditación (ENAC).
As part of the accreditation process, it is mandatory to provide
internal quality controls (IQC) and to participate in external qual-
ity assessment (EQA). IQC is an internal verification that the test
yields consistent results day after day and is defined as “the set of
procedures undertaken by the staff of a laboratory for continu-
ously assessing laboratory work and the emergent results, in
order to decide whether they are reliable enough to be released”
[69]. EQA implies testing of the same samples by different lab-
oratories. This assessmentmay be done either by cross-validation
of samples among laboratories or may be organized by external
agencies. In the case of BRCA1/2 assessment, this is covered by
the quality programs of the EMQN and GENQA.
These programs evaluate not only the technical performance
of producing analytical results from samples shared to all partic-
ipating laboratories but also the accuracy of the report produced
(data included from the patients, information regarding testing,
accuracy of databases employed), as well as the interpretation of
the genetic results. In the case of BRCA assessment, this is of
utmost importance as mutational assessment may not only in-
clude the detection of pathogenic variants but also VUS or be-
nign variants, which should be correctly identified. For this rea-
son, in recent years, some quality control assessments have been
only based in the interpretation of the BRCA1/2 variants, without
performing wet-lab testing.
Beyond BRCA Testing
Germline or somatic mutations in HR genes other thanBRCA1/2
have been reported in approximately 10%of ovarian carcinomas,
including both serous and non-serous histologies [51, 63]. In
addition, it has been observed that mutations in other HR genes
have a similar positive impact on OS and platinum responsive-
ness as BRCA1/2 mutations [51]. Finally, HRD can be assessed
by methods other than the analysis of mutations in HRD genes.
As a consequence of HRD, typical genomic alterations, such as
LOH, telomeric imbalance, and large-scale transitions, can be
accumulated and can be measured. Ovarian carcinomas with
high LOH (≥14–16%) determined by NGS showed good re-
sponse to rucaparib [62]. In addition, LOH, together with
telomeric allelic imbalance and large-scale transitions, generates
an HRD score (MyChoice® HRD test, Myriad Genetics Inc.,
Salt Lake City, Utah), which when ≥42 is associated to benefit
to olaparib [34, 40]. In accordance with these data, ESMO-
ESGO consensus conference recommended that testing for mu-
tations in other HR genes, in particular RAD51C/D, BRIP1, and
PALB2, should be considered in patient with ovarian cancer.
Current assays of HR function, although promising, cannot be
used to exclude patients from PARP inhibitor therapy [16].
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